Подходы к лекарственной терапии больных ХОБЛ стабильного течения: предлагаемый алгоритм лечения

СтатьяМЕД СОВЕТ. 2015; № 17: 24–31. DOI:10.21518/2079-701X-2015-17-24-31

Зыков К. А.^[1,2]

Овчаренко С. И.^[3]

^[1]Московский государственный медико-стоматологический университет им. А. И. Евдокимова

^[2]Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения РФ, ул. 3-я Черепковская, 15а, Москва, 121552, Российская Федерация

^[3]Первый Московский государственный медицинский университет им. И. М. Сеченова (Сеченовский университет)

Хроническая болезнь легких является одной из основных причин смертности в мире. Одной из наиболее актуальных задач, которые необходимо решить для улучшения качества ведения пациентов с данной патологией, является разработка алгоритмов ведения больных, которые могут применяться не только узкими специалистами, но и врачами общей практики и терапевтами. В статье авторы представляют клинический алгоритм медикаментозной терапии больных ХОБЛ стабильного течения, который позволит назначать терапию большинству пациентов в соответствии с современными рекомендациями в условиях реальной клинической практики.

хроническая обструктивная болезнь легких

рекомендации

алгоритм терапии

бронхолитики

ингаляционные глюкокортикостероиды

chronic obstructive pulmonary disease

treatment algorithm

long-acting bronchodilators

Алгоритмы

Болезнь

Боли

Больные

Врачи общей практики

Время

Диагностика

Коморбидность

Легкие

Легких болезнь хроническая обструктивная

Мокрота

Нейтрофилы

Одышка

Патология

Причинная связь

Пульмонологи

Риск

Смертность

Эозинофилы

Эукариоты

Федеральные клинические рекомендации по диагностике и лечению хронической обструк-тивной болезни легких. Российское респираторное общество. http://puLmonoLogy.ru/ downLoad/COPD2014may2.doc.http://puLmonoLogy.ru/

AL-Showair RA, Tarsin WY, Assi KH et aL. Can aLL patients with COPD use the correct inhaLation-fLow with aLL inhaLers and does training heLp? Respir Med, 2007. 101: 2395-401.

ALbert RK, Connett J, BaiLey WC, et aL. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, Aug 25. 365(8): 689-98.

Beghe B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J, 2013. Apr. 41(4): 993-5

BeLda J, Leigh R, Parameswaran K, O'Byrne PM, Sears MR, Hargreave FE. Induced sputum ceLL counts in heaLthy aduLts. Am J Respir Crit Care Med, 2000. 161: 475-478.

BuhL R,MaLtais F, Abrahams R et aL. Tiotropium and oLodateroL fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J, 2015. 45: 969-979.

CazzoLa M, Santus P, DAdda A et aL. Acute effects of higher than standard doses of saL-butamoL and ipratropium on tiotropium-induced bronchodiLation in patients with stabLe COPD. Pulm Pharmacol Ther, 2009. Jun. 22(3): 177-82.

Chetta A, OLivieri D. The COPD Assessment Test in the EvaLuation of Chronic Obstructive PuLmonary Disease Exacerbations. Expert Rev Resp Med, 2012. 6(4): 373-375

ChuchaLin A, KhaLtaev N, Antonov N. Исследование хронических респираторных заболеваний и факторов риска в 12 регионах Российской Федерации. http: //www.medLinks.ru/ articLe.php?sid=61101.

CoLe J, Sheehan A, Jordan J.Concomitant use of ipratropium and tiotropium in chronic obstructive puLmonary disease. Ann Pharmacother, 2012. Dec. 46(12): 1717-21.

Cooper C, Barjaktarevic I. A new aLgorithm for the management of COPD. Lancet Respir Med, 2015. Apr. 3(4): 266-8.

Dasgupta A, Neighbour H, Nair P. Targeted therapy of bronchitis in obstructive airway diseases. Pharmacol Ther, 2013. Dec. 140(3): 213-22.

Decramer M, CeLLi B, Kesten S et aL. Effect of tiotropium on outcomes in patients with moderate chronic obstructive puLmonary disease (UPLIFT): a prespecified subgroup anaLysis of a randomised controLLed triaL. Lancet, 2009. Oct 3. 374(9696): 1171-8.

Decramer ML, Chapman KR, DahL R et aL. Once-daiLy indacateroL versus tiotropium for patients with severe chronic obstructive puLmonary disease (INVIGORATE): a randomised, bLinded, paraLLeL-group study. Lancet Respir Med, 2013. Sep. 1(7): 524-33.

DonaLdson GC, SeemungaL TA, Bhowmik A, Wedzicha JA. ReLationship between exacerbation frequency and Lung function decLine in chronic obstructive puLmonary disease. Thorax, 2002. 57: 847-52.

Fexer J, Donnachie E, Schneider A et aL. The effects of theophyLLine on hospitaL admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program. Dtsch Arztebl Int, 2014. Apr 25. 111(17): 293-300.

Gao P, Zhang J, He X et aL. Sputum infLammatory ceLL-based cLassification of patients with acute exacerbation of chronic obstructive puLmonary disease. PLoS One, 2013. May 31. 8(5): e57678.

GLobaL strategy for the diagnosis, management, and prevention of chronic obstructive puLmonary disease GLobaL Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. AvaiLabLe from: http: //www.goLdcopd.org/

HaLpin DM, DahL R, HaLLmann C, MueLLer A, Tashkin D. Tiotropium HandiHaLer(®) and Respimat(®) in COPD: a pooLed safety anaLysis. Int J Chron Obstruct Pulmon Dis, 2015. Feb 5. 10: 239-59.

Han M, Agusti A, CaLverLey P et aL. Chronic obstructive puLmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med, 2010. Sep 1. 182(5): 598-604.

Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. InternationaL JournaL of COPD: 10 1093-1102

Hurst JR, Vestbo J, Anzueto A, et aL. SusceptibiLity to exacerbation in chronic obstructive puLmonary disease. N Engl J Med, 2010. 363: 1128-38.

Jenkins CR, Jones PW, CaLverLey PM, et aL. Efficacy of saLmeteroL/fLuticasone propionate by GOLD stage of chronic obstructive puLmonary disease: anaLysis from the randomised, pLacebo-controLLed TORCH study. Respir Res, 2009. 10: 59.

Jones P, Tabberer M, Chen W-H. Creating scenarios of the impact of COPD and their reLationship to COPD assessment test (CATTM) scores. BMC Pul Med, 2011. 11(1): 42.

Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of heaLth status scores with MRC grades in COPD: impLications for the GOLD 2011 cLassification. Eur Respir J, 2013. 42: 647-54.

Jones PW. HeaLth status and the spiraL of decLine. COPD, 2009. 6: 59-63.

Kanner RE, Anthonisen NR, Connett JE. Lower respiratory iLLnesses promote FEV(1) decLine in current smokers but not ex-smokers with miLd chronic obstructive puLmonary disease: resuLts from the Lung heaLth study. Am J Respir Crit Care Med, 2001. 164: 358-64.

KessLer R, StahL E, VogeLmeier C, et aL. Patient understanding, detection, and experience of COPD exacerbations: an observationaL, interview-based study. Chest, 2006. 130: 133-42.

Kon SS, Canavan JL, Jones SE et aL. Minimum cLinicaLLy important difference for the COPD Assessment Test: a prospective anaLysis. Lancet Respir Med, 2014. Mar. 2(3): 195-203.

Lee SD, Huang MS, Kang Jet aL. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Respir Med, 2014. Apr. 108(4): 600-8.

Lozano R, Naghavi M, Foreman K et aL. GLobaL and regionaL mortaLity from 235 causes of death for 20 age groups in 1990 and 2010: a systematic anaLysis for the GLobaL Burden of Disease Study 2010. Lancet, 2012. 380: 2095-2128.

Mackay AJ, DonaLdson GC, PateL AR et aL. UsefuLness of the Chronic Obstructive PuLmonary Disease Assessment Test to evaLuate severity of COPD exacerbations. Am J Respir Crit Care Med, 2012. Jun 1. 185(11): 1218-24.

MahLer D, Kerstjens H, Donohue J IndacateroL vs tiotropium in COPD patients cLassified as GOLD A and B. Respiratory Medicine, 2015. http: //dx.doi.org/10.1016/j.rmed.2015.05.012.

MahLer D, Kerwin E, Ayers T et aL.FLIGHT1 and FLIGHT2: Efficacy and Safety of OVA149 (IndacateroL/GLycopyrroLate) versus Its Monocomponents and PLacebo in Patients with Chronic Obstructive PuLmonary Disease. Am J Respir Crit Care Med, 2015. Nov 1. 192(9): 1068-79.

Makino S, Adachi M, Ohta K, et aL A prospective survey on safety of sustained-reLease theophyL-Line in treatment of asthma and COPD. Allergol Int, 2006. Dec. 55(4): 395-402.

Martinez FJ, CaLverLey PM, Goehring UM et aL. Effect of rofLumiLast on exacerbations in patients with severe chronic obstructive puLmonary disease uncontroLLed by combination therapy (REACT): a muLticentre randomised controLLed triaL. Lancet, 2015. Mar 7. 385(9971): 857-66.

Moritz P, SteidLe L, FeLisbino MB et aL. Determination of the infLammatory component of airway diseases by induced sputum ceLL counts: use in cLinicaL practice. J Bras Pneumol, 2008. Nov. 34(11): 913-21.

NMH/MND/CPM/13.1 GLobaL aLLiance against chronic respiratory diseases (GARD) 7th GeneraL Meeting, 9-10 JuLy 2012, St. Petersburg, Russia http: //www.who.int/gard/pubLications/ GARDGMReportStPetersburg2012.pdf.

Pascoe S, Locantore N, DransfieLd M et aL. BLood eosinophiL counts, exacerbations, and response to the addition of inhaLed fLuticasone furoate to viLanteroL in patients with chronic obstructive puLmonary disease: a secondary anaLysis of data from two paraLLeL randomised controLLed triaLs. Lancet Respir Med, 2015. Jun. 3(6): 435-42.

Язык текста: Русский

ISSN: 2079-701X